EBS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EBS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Emergent BioSolutions's current share price is $1.95. Emergent BioSolutions's E10 for the quarter that ended in Dec. 2023 was $0.03. Emergent BioSolutions's Shiller PE Ratio for today is 65.00.
The historical rank and industry rank for Emergent BioSolutions's Shiller PE Ratio or its related term are showing as below:
During the past years, Emergent BioSolutions's highest Shiller PE Ratio was 113.00. The lowest was 4.53. And the median was 33.04.
EBS's Shiller PE Ratio is ranked worse thanE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Emergent BioSolutions's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.880. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.03 for the trailing ten years ended in Dec. 2023.
The historical data trend for Emergent BioSolutions's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shiller PE Ratio | Get a 7-Day Free Trial | 7.51 | 8.21 | 10.17 | 19.56 | 76.85 |
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Emergent BioSolutions's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 1.95 | / | 0.03 | |
= | 65.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, Emergent BioSolutions's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.88 | / | 129.4194 | * | 129.4194 | |
= | -0.880 |
Current CPI (Dec. 2023) = 129.4194.
Emergent BioSolutions Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | -0.550 | 99.695 | -0.714 |
201406 | 0.130 | 100.560 | 0.167 |
201409 | 0.490 | 100.428 | 0.631 |
201412 | 0.660 | 99.070 | 0.862 |
201503 | -0.570 | 99.621 | -0.740 |
201506 | 0.320 | 100.684 | 0.411 |
201509 | 0.790 | 100.392 | 1.018 |
201512 | 0.710 | 99.792 | 0.921 |
201603 | 0.100 | 100.470 | 0.129 |
201606 | -0.270 | 101.688 | -0.344 |
201609 | 0.450 | 101.861 | 0.572 |
201612 | 0.670 | 101.863 | 0.851 |
201703 | 0.230 | 102.862 | 0.289 |
201706 | 0.110 | 103.349 | 0.138 |
201709 | 0.680 | 104.136 | 0.845 |
201712 | 0.670 | 104.011 | 0.834 |
201803 | -0.100 | 105.290 | -0.123 |
201806 | 0.980 | 106.317 | 1.193 |
201809 | 0.410 | 106.507 | 0.498 |
201812 | -0.070 | 105.998 | -0.085 |
201903 | -0.510 | 107.251 | -0.615 |
201906 | -0.180 | 108.070 | -0.216 |
201909 | 0.830 | 108.329 | 0.992 |
201912 | 0.890 | 108.420 | 1.062 |
202003 | -0.240 | 108.902 | -0.285 |
202006 | 1.730 | 108.767 | 2.058 |
202009 | 0.730 | 109.815 | 0.860 |
202012 | 3.440 | 109.897 | 4.051 |
202103 | 1.280 | 111.754 | 1.482 |
202106 | 0.090 | 114.631 | 0.102 |
202109 | -0.610 | 115.734 | -0.682 |
202112 | 3.500 | 117.630 | 3.851 |
202203 | -0.070 | 121.301 | -0.075 |
202206 | -1.130 | 125.017 | -1.170 |
202209 | -1.750 | 125.227 | -1.809 |
202212 | -1.760 | 125.222 | -1.819 |
202303 | -3.650 | 127.348 | -3.709 |
202306 | -5.150 | 128.729 | -5.178 |
202309 | -5.080 | 129.860 | -5.063 |
202312 | -0.880 | 129.419 | -0.880 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Emergent BioSolutions's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Neal Franklin Fowler | director | C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Donald W Degolyer | director | 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
William Hartzel | officer: SVP, Bioservices | 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879 |
Miller H Haywood Iii | officer: Interim CEO | EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Kathryn C Zoon | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Paul Anthony Williams | officer: SVP, Products Business | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Ronald Richard | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Sujata Tyagi Dayal | director | C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Glessner Coleen | officer: EVP, Quality & Ethics, and CPL | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Jennifer Lynne Fox | officer: EVP, Ext Aff, GC, Corp Sec | 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879 |
Richard S Lindahl | officer: EVP, Chief Financial Officer | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Sue Bailey | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850 |
Adam Havey | officer: EVP, BioDefense Division | 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853 |
Robert Kramer | officer: Interim, EVP, BioSciences | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
From GuruFocus
By Marketwired • 08-08-2023
By PurpleRose PurpleRose • 07-18-2022
By Value_Insider Value_Insider • 10-18-2022
By PurpleRose PurpleRose • 08-10-2022
By sperokesalga sperokesalga • 04-19-2023
By GlobeNewswire GlobeNewswire • 02-15-2023
By sperokesalga sperokesalga • 02-15-2023
By PRNewswire • 08-08-2023
By sperokesalga sperokesalga • 05-11-2023
By Value_Insider Value_Insider • 11-14-2022